Paper · 39282910

Perioperative Durvalumab with Neoadjuvant Chemotherapy in Operable Bladder Cancer.

Powles T and 25 others. N Engl J Med, 2024. Cited by 357 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Cite this record

ConductScience Library. Perioperative Durvalumab with Neoadjuvant Chemotherapy in Operable Bladder Cancer. Papers, record 39282910. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39282910

On this page

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title: Perioperative Durvalumab with Neoadjuvant Chemotherapy in Operable Bladder Cancer.; PubMed
Journal: N Engl J Med; PubMed
Year: 2024; PubMed
Publication types: Journal Article, Clinical Trial, Phase III, Randomized Controlled Trial, Multicenter Study, Comparative Study, Research Support, N.I.H., Extramural; PubMed
PubMed: https://pubmed.ncbi.nlm.nih.gov/39282910/; PubMed
DOI: https://doi.org/10.1056/nejmoa2408154; PubMed
The journal: https://conductscience.org/library/journal-index/0255562; PubMed
Citations, by iCite: 357; iCite
Relative citation ratio, by iCite: 43.61, provisional; iCite
Revised in PubMed: 2026-05-18; PubMed

Authors26

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

Order	Author	Forename	ORCID iD
1	Powles T	Thomas
2	Catto JWF	James W F	https://orcid.org/0000-0003-2787-8828
3	Galsky MD	Matthew D
4	Al-Ahmadie H	Hikmat	https://orcid.org/0000-0002-2938-6627
5	Meeks JJ	Joshua J
6	Nishiyama H	Hiroyuki
7	Vu TQ	Toan Quang
8	Antonuzzo L	Lorenzo
9	Wiechno P	Pawel
10	Atduev V	Vagif

1 to 10 of 26Source PubMed

See all 26 authors

Topics20

NLM's MeSH indexing of the paper, its major topics first.

MeSH term	Major
Antibodies, Monoclonal	Major topic
Antineoplastic Combined Chemotherapy Protocols	Major topic
Cystectomy	Major topic
Deoxycytidine	Major topic
Urinary Bladder Neoplasms	Major topic
Antineoplastic Agents, Immunological	Major topic
Adult
Aged
Female
Humans
Male
Middle Aged
Chemotherapy, Adjuvant
Cisplatin
Gemcitabine
Kaplan-Meier Estimate
Neoadjuvant Therapy
Progression-Free Survival
Survival Analysis
Aged, 80 and over

Source PubMed

Grants2

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes it	Agency	Country	NIH project	Stated by	Source
N/A	AstraZeneca			PubMed	PubMed
			P30CA086862	NIH	NIH RePORTER

Trials1

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

Trial	Title	The trial lists it as	Named in the paper's record
NCT03732677	Durvalumab+ Gemcitabine/Cisplatin (Neoadjuvant Treatment) and Durvalumab (Adjuvant Treatment) in Patients With MIBC	Derived from the trial	Yes

Source ClinicalTrials.gov

Comments and corrections2

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

Kind	PMID	Title	In Papers	Source
Comment in	39,908,437	Perioperative Durvalumab in Bladder Cancer.	https://conductscience.org/library/papers/39908437	PubMed
Comment in	39,908,438	Perioperative Durvalumab in Bladder Cancer. Reply.	https://conductscience.org/library/papers/39908438	PubMed

References0

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

None in this release.

Cited by229

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 357 citations.

PMID	Title	Journal	Year	In Papers	Source
42,985,962	The Combined Value of the Prognostic Nutritional Index and Pan-Immune-Inflammation Value in Predicting Neoadjuvant Chemotherapy and Survival in Locally Advanced Colon Cancer: A Retrospective Study.	Immun Inflamm Dis	2026	https://conductscience.org/library/papers/42985962	PubMed
42,985,454	Optimal timing of adjuvant immunotherapy after radical cystectomy in muscle-invasive bladder cancer: from calendar-based to MRD-guided decision making.	Front Oncol	2026	https://conductscience.org/library/papers/42985454	PubMed
42,977,952	Evolution of treatment distribution and patient characteristics of muscle invasive bladder cancer patients: results from two multi-national real-world surveys.	BMC Urol	2026	https://conductscience.org/library/papers/42977952	PubMed
42,968,952	Prognostic Impact of Nectin4 and IRF6 Expression in Patients Undergoing Radical Cystectomy for Muscle-Invasive Bladder Cancer.	Cancer Diagn Progn	2026	https://conductscience.org/library/papers/42968952	PubMed
42,941,374	Robot-Assisted Radical Cystectomy with Intracorporeal Urinary Diversion: Perioperative Management and Operative Technique.	J Clin Med	2026	https://conductscience.org/library/papers/42941374	PubMed
42,932,116	Patient-Derived Organoids for Predicting Chemotherapy Response in Bladder Cancer: A Multicenter, Real-world Validation Study.	Ann Surg Oncol	2026	https://conductscience.org/library/papers/42932116	PubMed
42,926,233	Neoadjuvant nivolumab with or without visugromab in muscle-invasive bladder cancer: the phase 2a GDFATHER-NEO trial.	Nat Med	2026	https://conductscience.org/library/papers/42926233	PubMed
42,911,273	Before the seeds arrive: pre-metastatic niche orchestration in bladder cancer.	Cancer Metastasis Rev	2026	https://conductscience.org/library/papers/42911273	PubMed
42,900,471	Cost-Effectiveness of Perioperative Enfortumab Vedotin and Pembrolizumab for Bladder Cancer.	JAMA Netw Open	2026	https://conductscience.org/library/papers/42900471	PubMed
42,866,863	Nerve-sparing radical cystectomy in the era of perioperative enfortumab vedotin plus pembrolizumab: reappraising the value of functional preservation.	Transl Androl Urol	2026	https://conductscience.org/library/papers/42866863	PubMed

1 to 10 of 229

See all 229 cited by

Genes0

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

None in this release.

Drugs3

The drugs whose trials, in the Pipelines release, list the paper.

Drug	ChEMBL ID	The trials list it as	Trials	In Drugs and targets	Source
CISPLATIN	CHEMBL11359	Derived from the trial	1	https://conductscience.org/library/drugs/CHEMBL11359	ChEMBL
DURVALUMAB	CHEMBL3301587	Derived from the trial	1	https://conductscience.org/library/drugs/CHEMBL3301587	ChEMBL
GEMCITABINE	CHEMBL888	Derived from the trial	1	https://conductscience.org/library/drugs/CHEMBL888	ChEMBL

Data1

The data bank entries PubMed's record names. Trial numbers are under Trials.

Data bank	Accession
EudraCT	2018-001811-59

Source PubMed

Data dates

The date of each source this release read.

PubMed: 2026-11-06; PubMed
iCite: 2026-11-05; iCite
PMC's ID file: 2026-11-05; PMC's ID file
NIH RePORTER's grant and paper links: 2026-11-01; NIH RePORTER's grant and paper links
Trials: 2026-11-12
Gene search: 2026-11-11
Pipelines: 2026-09-18

Sources 11

ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
HGNCCC0
iCiteCC BY 4.0
NCBI GenePublic domain (US government)
NIH RePORTER's grant and paper linksPublic domain
Open TargetsCC0 1.0
PMC's ID filePublic domain (US government)
PubMedNLM's terms
PubTator 3Public domain
UniProtCC BY 4.0

Each source's terms

ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
HGNCCC0: https://www.genenames.org/about/license/
iCiteCC BY 4.0
NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
PubMedNLM's terms
PubTator 3Public domain
UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/39282910

GET https://conductscience.org/api/papers/v1/39282910/authors?page=2

API reference For AI assistants